Tiziana Life Sciences to Present at BIO-Europe in Vienna, Highlighting Innovative Immunomodulation Therapy
Tiziana Life Sciences (Nasdaq: TLSA) will present at BIO-Europe 2025 in Vienna on November 3–5, 2025, where management led by CEO Ivor Elrifi will hold one-on-one partnering meetings with biopharma executives and investors.
The presentation will highlight Tiziana’s intranasal foralumab, a fully human anti-CD3 monoclonal antibody in clinical development, and the company’s nasal delivery platform aimed at improving efficacy, safety, and tolerability versus IV dosing. Ongoing programs include Phase 2 trials in non-active secondary progressive MS (na-SPMS) and Multiple System Atrophy (MSA); Phase 2 studies in early Alzheimer’s disease and amyotrophic lateral sclerosis (ALS) are planned to commence.
BIO-Europe 2025 is expected to attract over 5,700 delegates from 60+ countries, offering partnering opportunities to advance Tiziana’s immunomodulation pipeline.
Tiziana Life Sciences (Nasdaq: TLSA) sarà presente a BIO-Europe 2025 a Vienna dal 3 al 5 novembre 2025, dove il management guidato dal CEO Ivor Elrifi terrà incontri di partnering one-on-one con dirigenti biopharma e investitori.
La presentazione metterà in evidenza l'intranasale foralumab di Tiziana, un anticorpo monoclonale anti-CD3 completamente umano in sviluppo clinico, e la piattaforma di somministrazione nasale dell'azienda finalizzata a migliorare efficacia, sicurezza e tollerabilità rispetto alla somministrazione endovenosa. I programmi in corso includono studi di Fase 2 in sclerosi multipla secondaria progressiva non attiva (na-SPMS) e atrofia sistemica multipla (MSA); sono previsti studi di Fase 2 in Alzheimer precoce e sclerosi laterale amiotrofica (ALS).
BIO-Europe 2025 dovrebbe attirare oltre 5.700 delegati provenienti da oltre 60 paesi, offrendo opportunità di partnering per avanzare il portfolio di immunomodulazione di Tiziana.
Tiziana Life Sciences (Nasdaq: TLSA) se presentará en BIO-Europe 2025 en Viena del 3 al 5 de noviembre de 2025, donde la dirección, liderada por el director ejecutivo Ivor Elrifi, mantendrá reuniones de asociación individual con ejecutivos de biofarma e inversores.
La presentación destacará el intranasal foralumab de Tiziana, un anticuerpo monoclonal anti-CD3 totalmente humano en desarrollo clínico, y la plataforma de entrega nasal de la empresa destinada a mejorar la eficacia, seguridad y tolerabilidad frente a la dosificación IV. Los programas en curso incluyen ensayos de Fase 2 en esclerosis múltiple secundaria progresiva no activa (na-SPMS) y atrofia sistémica múltiple (MSA); están previstos estudios de Fase 2 en las primeras etapas de la enfermedad de Alzheimer y en la esclerosis lateral amiotrófica (ALS).
BIO-Europe 2025 se espera que atraiga a más de 5.700 delegados procedentes de 60+ países, ofreciendo oportunidades de partnering para avanzar la cartera de inmunomodulación de Tiziana.
Tiziana Life Sciences (나스닥: TLSA)는 2025년 11월 3일부터 5일까지 빈에서 열리는 BIO-Europe 2025에 발표할 예정이며, CEO 아이버 엘리프리(Ivor Elrifi)가 이끄는 경영진이 생물의학 제약사 임원 및 투자자들과 1대1 파트너링 미팅을 가질 예정입니다.
발표에서는 임상 개발 중인 완전 인간형 anti-CD3 단클론 항체인 intranasal foralumab과 비강 전달 플랫폼을 강조하여 정맥 투여 대비 효과, 안전성 및 내약성을 개선하는 것을 목표로 합니다. 진행 중인 프로그램으로는 비활성의 이차 진행성 다발성경화증(na-SPMS) 및 다발성 시스템 위축증(MSA)에서의 2상 임상시험이 포함되며, 조기 알츠하이머병 및 근위축성 측삭경화증(ALS)에서의 2상 연구가 시작될 예정입니다.
BIO-Europe 2025는 60개국 이상에서 5,700명 이상의 대리인이 참석할 것으로 예상되며, Tiziana의 면역조절 파이프라인을 발전시키기 위한 파트너링 기회를 제공할 것입니다.
Tiziana Life Sciences (Nasdaq: TLSA) sera présent à BIO-Europe 2025 à Vienne du 3 au 5 novembre 2025, où la direction dirigée par le PDG Ivor Elrifi tiendra des réunions de partenariat en tête-à-tête avec des cadres biopharma et des investisseurs.
La présentation mettra en évidence le foralumab intranasal de Tiziana, un anticorps monoclonal anti-CD3 entièrement humain en développement clinique, et la plateforme de délivrance nasale de l'entreprise visant à améliorer l'efficacité, la sécurité et la tolérabilité par rapport à la posologie IV. Les programmes en cours comprennent des essais de phase 2 dans la sclérose en plaques secondaire progressive non active (na-SPMS) et l’atrophie multisystémique (MSA); des études de phase 2 dans les formes précoces de la maladie d’Alzheimer et dans la sclérose latérale amyotrophique (ALS) sont prévues.
BIO-Europe 2025 devrait attirer plus de 5 700 délégués venus de plus de 60 pays, offrant des opportunités de partenariat pour faire progresser le portefeuille d’immunomodulation de Tiziana.
Tiziana Life Sciences (Nasdaq: TLSA) wird bei BIO-Europe 2025 in Wien vom 3. bis 5. November 2025 präsentieren, wobei das Management unter der Leitung des CEO Ivor Elrifi One-on-One-Partnering-Meetings mit Biopharma-Führungskräften und Investoren abhalten wird.
Die Präsentation wird Tizianas intranasales Foralumab hervorheben, einen vollständig humanen anti-CD3-Monoklonalen Antikörper in klinischer Entwicklung, sowie die nasale Verabreichungsplattform des Unternehmens, die darauf abzielt, Wirksamkeit, Sicherheit und Verträglichkeit gegenüber der IV-Dosierung zu verbessern. Laufende Programme umfassen Phase-2-Studien bei nicht aktiver sekundär-progressiver MS (na-SPMS) und Multipler Systematrophie (MSA); Phase-2-Studien in der frühen Alzheimer-Krankheit und Amyotropher Lateralsklerose (ALS) sind geplant.
BIO-Europe 2025 wird voraussichtlich über 5.700 Delegierte aus mehr als 60 Ländern anziehen und bietet Partnerschaftsmöglichkeiten, um Tizianas Immunmodulations-Pipeline voranzubringen.
تيزيانا لايف ساينسز (ناسداك: TLSA) ستقدّم في BIO-Europe 2025 في فيينا في الفترة من 3 إلى 5 نوفمبر 2025، حيث ستعقد الإدارة بقيادة الرئيس التنفيذي إيفور إليفي اجتماعات شراكة فردية مع مسؤولي شركات الأدوية الحيوية والمستثمرين.
سيبرز العرض فورالوماب الأنفي من تيزيانا، وهو جسم مضاد أحادي النسيلة بشري كامل مضاد لـCD3 قيد التطوير السريري، ومنصة التوصيل الأنفي للشركة التي تهدف إلى تحسين الفاعلية والسلامة وال tolerability مقارنة بالجرعة الوريدية. تشمل البرامج الجارية تجارب المرحلة الثانية في التصلب المتعدد الثانوية غير النشط المنتشر (na-SPMS) والضمور العضلي المتعدد (MSA)؛ ومن المخطط أن تبدأ دراسات المرحلة الثانية في مرض الزهايمر في مراحله المبكرة و التصلب الجانبي الضموري (ALS).
من المتوقع أن يجتذب BIO-Europe 2025 أكثر من 5,700 مندوب من 60+ دولة، وهو ما يوفر فرص شراكة لتطوير محفظة المناعة التنظيمية لـ تيزيانا.
Tiziana Life Sciences (Nasdaq: TLSA) 将于 BIO-Europe 2025 在维也纳举行，时间为 2025 年 11 月 3-5 日，届时由首席执行官 Ivor Elrifi 领导的管理团队将与生物制药高管和投资者进行一对一的合作洽谈。
此次演讲将重点介绍 Tiziana 的 intranasal foralumab，这是一个正在临床开发的完全人源 anti-CD3 单克隆抗体，以及公司用于鼻腔给药的平台，旨在提高相对于静脉给药的有效性、安全性和耐受性。正在进行的项目包括非活动性继发进展性MS (na-SPMS) 和多系统锥谱? 多系统萎缩 (MSA) 的 Phase 2 试验；早期阿尔茨海默病和肌萎缩侧索硬化症（ALS）的 Phase 2 研究计划启动。
BIO-Europe 2025 有望吸引来自 60 多个国家的超过 5,700 名代表，为推进 Tiziana 的免疫调节管线提供合作机会。
- None.
- None.
BOSTON, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully human, anti-CD3 monoclonal antibody, today announced its participation as a presenting company at BIO-Europe 2025. The event, Europe’s premier life sciences partnering conference, will take place November 3–5, 2025, at the Vienna Exhibition and Congress Center (Messe Wien) in Vienna, Austria.
Tiziana’s management team, led by CEO Ivor Elrifi, will also engage in one-on-one partnering meetings with leading biopharma executives and investors. The Company’s presentation will focus on its innovative nasal delivery platform and lead candidate, intranasal foralumab—the only fully human anti-CD3 monoclonal antibody in clinical development. This proprietary approach aims to enhance efficacy, safety, and tolerability over traditional intravenous methods, targeting neuroinflammatory and neurodegenerative diseases such as non-active secondary progressive multiple sclerosis (na-SPMS), Multiple System Atrophy (MSA), and early Alzheimer’s disease.
“We are excited to showcase Tiziana’s progress at BIO-Europe 2025, a pivotal forum for forging strategic partnerships that can accelerate our pipeline toward commercialization,” said Ivor Elrifi, CEO of Tiziana Life Sciences. “Building on our ongoing Phase 2 clinical trials in na-SPMS and MSA, we are about to commence Phase 2 studies in early Alzheimer’s disease and in amyotrophic lateral sclerosis (“ALS”). We look forward to discussing how our intranasal foralumab can address unmet needs in immunotherapy and drive meaningful patient outcomes.”
BIO-Europe 2025 is expected to draw over 5,700 delegates from more than 60 countries, facilitating thousands of targeted partnering meetings. Tiziana’s participation underscores its commitment to advancing novel therapies that modulate immune responses through alternative delivery routes, potentially transforming treatment paradigms for chronic neurological conditions.
About Foralumab
Foralumab, a fully human anti-CD3 monoclonal antibody, is a biological drug candidate that has been shown to stimulate T regulatory cells when dosed intranasally. At present, 14 patients with Non-Active Secondary Progressive Multiple Sclerosis (na-SPMS) have been dosed in an open-label intermediate sized Expanded Access (EA) Program (NCT06802328) with either an improvement or stability of disease seen within 6 months in all patients. In addition, intranasal foralumab is currently being studied in a Phase 2a, randomized, double-blind, placebo-controlled, multicenter, dose-ranging trial in patients with non-active secondary progressive multiple sclerosis (NCT06292923).
Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) currently in clinical development. Immunomodulation by intranasal foralumab represents a novel avenue for the treatment of neuroinflammatory and neurodegenerative human diseases.[1],[2]
About Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company developing breakthrough therapies using transformational drug delivery technologies to enable alternative routes of immunotherapy. Tiziana’s innovative nasal approach has the potential to provide an improvement in efficacy as well as safety and tolerability compared to intravenous (IV) delivery. Tiziana’s lead candidate, intranasal foralumab, which is the only fully human anti-CD3 mAb currently in clinical development, has demonstrated a favorable safety profile and clinical response in patients in studies to date. Tiziana’s technology for alternative routes of immunotherapy has been patented with several applications pending and is expected to allow for broad pipeline applications.
For more information about Tiziana Life Sciences and its innovative pipeline of therapies, please visit www.tizianalifesciences.com.
For further inquiries:
Tiziana Life Sciences Ltd
Paul Spencer, Business Development, and Investor Relations
+44 (0) 207 495 2379
email: info@tizianalifesciences.com
[1] https://www.pnas.org/doi/10.1073/pnas.2220272120
[2] https://www.pnas.org/doi/10.1073/pnas.2309221120
FAQ
When and where will Tiziana Life Sciences (TLSA) present at BIO-Europe 2025?
What will Tiziana (TLSA) present about at BIO-Europe 2025?
Which clinical programs will Tiziana (TLSA) highlight at the conference?
How many delegates is BIO-Europe 2025 expected to draw and why does it matter for TLSA?
Who will represent Tiziana (TLSA) at BIO-Europe 2025 and what meetings are planned?
